The NABOTA Vision

Daewoong Pharmaceutical announced its vision for ‘NABOTA’ sweeping the global botulinum toxin market

- A large-scale press conference was held to announce domestic roll-out of NABOTA and global vision on April 16

- NABOTA has reached a milestone of KRW 700 billion in cumulative export sales, poised to hit the record high exports in domestic pharmaceutical industry

- CEO and other high-ranking officials of U.S.-based Evolus visited Korea and put forward blueprint for NABOTA making a clean sweep of U.S. and European market 

Nabota Photos from the 72nd Korean Plastic Surgery Meet in Seoul

Nabota launched by Chris Cachuela in the Philippines

Daewoong Pharmaceutical became the first in pharmaceutical industry to receive AA-grade in CP evaluation

AA-grade in CP evaluation is the highest rating ever received by a domestic pharmaceutical company.

Daewoong Pharmaceutical received highest rating in recognition of voluntary compliance efforts, such as introduction of CP for internal purification and department dedicated to fair trade affairs.

Daewoong Pharmaceutical is writing a new chapter in the history of fair trade in pharmaceutical industry.

Daewoong Pharmaceutical Co.,Ltd(President: Lee Jong-wook) announced on January 2 that it received AA grade in Korea Fair Trade Commission's Compliance Program(CP). AA grade is the highest grade ever received not only by a pharmaceutical company but also the entire industry.

CP refers to the internal compliance system introduced and operated voluntarily by companies to comply with the laws and regulations related to fair trade. AA-grade in CP signifies unparalleled excellence in the operation of CP with structural, operational, and sustainable factors kept in balance. Particularly, Korea Fair Trade Commission awards official grade certificate to companies that received ratings above A-grade.

Daewoong Pharmaceutical introduced the CP for internal purification after the Korea Fair Trade Commission's investigation in 2007.  Specifically, Daewoong Pharmaceutical has been fully committed to voluntary compliance, proceeding ahead with promotion and dissemination of Code of Conduct for all employees, regular preparation and distribution of CP guideline and CEO message, scheduled/unscheduled education, internal audit, incorporation of CP regulation into company rules/regulations. Daewoong Pharmaceutical set up the Compliance Team under direct control of CEO to handle the matters related to fair trade in April 2014.


In the Philippines, Daewoong Pharma Phils Inc, has launched NABOTA. Nabota is a novel botulinum toxin that was a product of a 5 year research.

Nabota marketing strategies and sales is being managed by its country Brand Manager Chris Cachuela.

From:
www.daewoong.com
www.nabota.info

Korean company seeks 15% share of PHL aesthetic market

Nabota Philippines Brand Manager Christopher Cachuela told the BusinessMirror that the country has a big potential for beauty-enhancing products given the increasing number of Filipinos who are conscious of their looks, apart from well-being.

Industry figures show that the local market for aesthetic products grows in a year by 11 percent, and this is projected to further rise as the country’s flourishing economy and strong buying power of consumers continue.

Read more by clicking the link below.

http://www.businessmirror.com.ph/korean-company-seeks-15-
share-of-phl-aesthetic-market/

Daewoong Pharmaceutical's NABOTA®, sets foot in the Philippines

NABOTA®, is the latest Clostridium Botulinum Toxin Type A that boasts of High Purity which makes it safe. Its stability leads to longer shelf life. Compared to the existing brands, NABOTA® has faster effect and longer duration. Developed from bio-technology of over 30 years of know-how and manufactured from Daewoong’s world class GMP, NABOTA® is widely accepted to more than 90 countries worldwide including US and European Union nations.

The NABOTA® Philippine Launch was actually historic as this is the first time that all 7 societies from the field of aesthetic medicine (Phil. Dermatological Society, Phil. Academy of Dermatologic Surgery Foundation, Phil. Assn. of Plastic and Reconstructive Surgery, Phil. Academy of Clinical & Cosmetic Dermatology, Phil. Academy of Aesthetic and Age-Management Medicine Inc., Phil. Association of Primary Skin Health Physicians, Inc., Phil. Academy of Aesthetic Surgery) supported the event alongside more than 500 doctors.

Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company for 2015.

In the Philippines, NABOTA® is exclusively marketed by Daewoong Pharma Phils. Inc. under the leadership of its experienced Brand Manager Christopher Cachuela who has been promoting dermatology products for more than 10 years. Daewoong Phils has successfully registered and launched over 37 brands in the market.
With NABOTA® entering the Philippine market, Filipinos can now achieve natural beauty safely and effectively.

Chris Cachuela Launches Nabota in the Philippines

Today, Nabota is widely used in different countries. Daewoong Pharma has successfully closed a series of contracts to export Nabota to the United States, Latin America, and Middle East countries. What’s more, the Daewoong Pharma has built the cooperation system with global pharma companies to achieve its goal of exporting Nabota to more than 90 countries including Canada and Asian countries.

NABOTA® is exclusively marketed by Daewoong Pharma Phils. Inc. under the leadership of its experienced Brand Manager Christopher Cachuela who has been promoting dermatology products for more than 10 years. Daewoong Phils has successfully registered and launched over 37 brands in the Philippines.

NABOTA is World Class Product 2014 #nabota #nabotaph

NABOTA, the botulinum toxin formulation of Daewoong Pharmaceutical, was named the World-Class Product of 2014

Daewoong Pharmaceutical signed contracts worth KRW 700 billion to export NABOTA to about 60 countries, cementing its undisputed leadership position in global market

NABOTA proved its potential for world’s top-selling product and Daewoong Pharmaceutical’s unrivaled technological prowess.

Daewoong Pharmaceutical Co.,Ltd(President: Lee Jong-wook) announced on December 9 that NABOTA, a botulinum toxin formulation developed with its own technology, was honored with the World-Class Product designation in 2014 World-Class Product Award held in COEX, Samseong-dong, Gangnam-gu. Seoul.

For more info please visit www.nabota.info